|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||37.24 / 45.49|
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
The pharmaceuticals company, led by CEO Joe Jiminez, had its first full quarter of generic competition for its Gleevec cancer drug.
As a bombed-out pound leaves British assets at a discount, who will be next in the post-Brexit M&A binge?
The U.K. isn't going anywhere Brexit vote notwithstanding, and here's a way to get on the most business-friendly state across the pond.
Bank of England defies market expectations and keeps rate at 0.5%; expects easing in August.
Shares in the U.K.'s leading pharmaceuticals company have risen about 20% since the June 23 Brexit vote.
Bank of England defies market expectations and keeps rate at 0.5%
UniCredit rises after the bank's chairman says asset sales won't address ECB capital demands, while BASF gains in Frankfurt on talk of the transfer of an agricultural unit to Monsanto.
Pfizer, Merck and GlaxoSmithKline are all producing blockbuster vaccines and have others in their pipelines.
If you think the best thing to do post-Brexit is buy more, here are 4 to consider.
'Shark Tank's' Kevin O'Leary joined CNBC's 'Fast Money Halftime Report' to talk about the selloff in European Markets and the companies he bought on his European shopping spree.
U.K.-listed drugs companies are likely to remain in rude health even if Britain stumbles post Brexit.
Trade-Ideas LLC identified GlaxoSmithKline (GSK) as a pre-market laggard candidate
GSK has been largely stuck between $44 on the upside and $37 on the downside for the past 12 months.
Regardless of which way the vote goes, these five companies based across the pond are teetering on the edge of big potential sell signals.
These 3 dividend stocks are rated a Hold by TheStreet
Trade-Ideas LLC identified GlaxoSmithKline (GSK) as a pre-market leader candidate
These high-yield dividend stocks are under pressure from the possibility of Britain leaving the European Union. While some may see this as an opportunity, the technical analysis says otherwise.
Brexit fears are creating opportunities to buy these three established high-dividend businesses at a discount.
With no outright denial of the story to kill it, Perrigo's share rose further in Tel Aviv overnight on a day-old rumor of a $20 billion takeover deal.
GlaxoSmithKline (GSK) stock is retreating this afternoon as its chairman of vaccines will retire next year.
TheStreet highlights 3 stocks pushing the health care sector lower today.
It's time to unload these toxic stocks from your portfolio.
Final purchasing managers' data for the eurozone come in better than initial estimates.
It’s already in the overbought territory, but by Monday it’s expected to be maximum overbought.